AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Third-generation vaccine against smallpox tested.
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Not everybody can safely be vaccinated against smallpox using the current U.S. Food and Drug Administration-approved vaccine.
Scientists hope another study vaccine, now undergoing its first testing in the U.S. at St. Louis University, will give a choice to people who can't be given the current vaccine, known as Dryvax.
"There are limits to the current vaccine," said Sharon Frey, MD, from St. Louis University's Center for Vaccine Development. "You can't give Dryvax to people with certain skin conditions, such as eczema, or to people who are immunosuppressed. So, for example, if you are HIV-positive or undergoing chemotherapy for cancer, you shouldn't receive the currently licensed vaccine."
Frey said this study vaccine, known as MVA-BN and provided through Bavarian Nordic, is different than other vaccines that are now available. Like the current vaccines, the study vaccine is a live-virus vaccine made from vaccinia virus, but this study vaccine contains a much more attenuated form of the virus.
"The thinking is that the study vaccine is ...
- In mouse study, vaccine prevents, suppresses neoplastic lesions.
- Newspaper article from: Vaccine Weekly March 17, 2004 700+ words
...information about this work, contact Federica Cavallo, federica.cavallo@unito.it. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- $1M contract signed to study vaccine against plague.
- Newspaper article from: Vaccine Weekly June 9, 2004 700+ words
...terror. As such, we are proud to be on the cutting-edge of this important effort." This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx.net.
- Study: vaccine safety parental concern.
- News wire article from: United Press International December 15, 2003 700+ words
NEW YORK, Dec 15, 2003 (United Press International via COMTEX) Doctors say U.S. parents seem more concerned about vaccine safety than in the past, according to a new survey. Four out of five doctors surveyed in 2000 reported at least one instance of parents refusing to have a child vaccinated
- BRIEF: Study: Vaccine protects against poisoning from inhaled, ingested ricin.
- Newspaper article from: Dallas Morning News (Dallas, TX) September 9, 2007 700+ words
Byline: Sue Goetinck Ambrose Sep. 9--An experimental vaccine against the deadly toxin ricin protects mice when the toxin is either inhaled or ingested, Dallas researchers have reported. Previous research, led by Ellen Vitetta at UT Southwestern Medical Center, showed that the vaccine prevents death
- Covalent Group Signs $1.0 Million Contract to Study Vaccine Against Plague.
- Press release article from: PR Newswire May 5, 2004 700+ words
Company's Third Counter-Bioterrorism Contract Covalent Group, Inc. today announced the signing of its third counter-bioterrorism vaccines contract within the past five months. This $1.0 million contract with DynPort Vaccine Company LLC (DVC) is for a Phase 1 study for the development of a
- UPI NewsTrack Health and Science News, Study: vaccine safety parental concern.
- News wire article from: United Press International December 15, 2003 700+ words
NEW YORK, Dec 15, 2003 (United Press International via COMTEX) Doctors say U.S. parents seem more concerned about vaccine safety than in the past, according to a new survey. Four out of five doctors surveyed in 2000 reported at least one instance of parents refusing to have a child vaccinated
- ID Biomedical begins trivalent nasal flu vaccine study.(Vaccine for prevention...
- Newspaper article from: BIOTECH Patent News December 1, 2001 700+ words
ID Biomedical Corporation (Vancouver, Canada; 604-431-9314) announced that it received permission from Health Canada to proceed with the Phase I Clinical Trial of FluINsure, a vaccine for the prevention of influenza that is administered by nasal spray. Additionally, the company announced that it
- DENDREON GETS OK TO RESUME ENROLLMENT IN PHASE III STUDY.(vaccine for...
- Magazine article from: BIOWORLD Today Coghill, Kim October 29, 2002 700+ words
Following a six-month delay, Dendreon Corp. received FDA clearance to resume enrollment in its second Phase III trial of Provenge, a therapeutic vaccine for hormone-resistant prostate cancer patients. The FDA forced Dendreon to suspend new enrollment of study D9902 in May pending submission of
Source: HighBeam Research, Third-generation vaccine against smallpox tested.